G-1 (CAS 881639-98-1): Selective GPR30 Agonist for Precision Signaling Research

Executive Summary: G-1 (CAS 881639-98-1) is a potent, selective agonist of the G protein-coupled estrogen receptor GPR30 (GPER1) with a Ki of ~11 nM and minimal off-target activity at ERα/ERβ even at micromolar concentrations (APExBIO). Upon binding, G-1 triggers rapid, non-genomic estrogenic signaling, including PI3K-dependent nuclear PIP3 accumulation and intracellular calcium elevation (EC50 = 2 nM) (Wang et al., 2021). In breast cancer models, G-1 exhibits nanomolar inhibition of cell migration, and in cardiac models demonstrates robust anti-fibrotic and contractility benefits. G-1 is insoluble in water and ethanol but dissolves in DMSO to ≥41.2 mg/mL, supporting high-concentration stock preparations. This review clarifies mechanistic, operational, and interpretive boundaries for reliable deployment of G-1 in endocrine, cardiovascular, and oncology workflows.

Biological Rationale

GPR30 (GPER1) is a membrane-bound estrogen receptor that mediates rapid, non-classical estrogenic signaling. Unlike nuclear estrogen receptors ERα and ERβ, GPR30 is primarily localized to the endoplasmic reticulum and plasma membrane. Activation of GPR30 is implicated in diverse physiological processes, including immune modulation, cardiovascular homeostasis, and tumor biology (Wang et al., 2021). The canonical ligand, 17β-estradiol, activates both nuclear and membrane receptors, complicating mechanistic dissection. G-1 was developed as a highly selective GPR30 agonist to address this gap, enabling researchers to isolate GPR30-mediated effects without significant interference from ERα/ERβ pathways (Related internal—this article extends mechanistic detail and parameterization for practical design).

Mechanism of Action of G-1 (CAS 881639-98-1), a selective GPR30 agonist

G-1 binds GPR30 with a Ki of ~11 nM, exhibiting >100-fold selectivity over ERα and ERβ, verified by radioligand binding and functional assays. Upon GPR30 engagement, G-1 initiates PI3K-dependent accumulation of nuclear PIP3 and rapidly increases intracellular Ca²⁺ levels (EC50 = 2 nM). These events trigger downstream signaling, modulating cell migration, proliferation, and fibrotic responses. In immune cells, G-1 normalizes CD4+ T lymphocyte function following stress by attenuating endoplasmic reticulum stress (ERS) via GPR30, not ERβ (Wang et al., 2021). In cardiac tissue, G-1 shifts β-adrenergic receptor expression (downregulating β1, upregulating β2), contributing to reduced fibrosis and improved contractility after injury (Related internal—here, we provide additional quantitative efficacy data and solubility parameters).

Evidence & Benchmarks

• G-1 binds GPR30 with a Ki of ~11 nM, showing negligible affinity for ERα and ERβ at concentrations up to 1 μM (APExBIO).
• Activation of GPR30 by G-1 elevates intracellular calcium (EC50 = 2 nM) in cell-based assays (Wang et al., 2021, Fig. 1).
• In SKBr3 and MCF7 breast cancer cells, G-1 inhibits migration with IC50 values of 0.7 nM and 1.6 nM, respectively (APExBIO).
• In a Sprague-Dawley rat model of heart failure, chronic G-1 dosing reduced brain natriuretic peptide (BNP), inhibited cardiac fibrosis, and improved contractility (6-week, i.p., 50 μg/kg/day) (Wang et al., 2021).
• Functional rescue of CD4+ T lymphocyte proliferation after hemorrhagic shock was observed with G-1 treatment, but not with ERβ agonists, confirming GPR30 specificity (Wang et al., 2021).

Applications, Limits & Misconceptions

G-1 is widely used to study rapid, non-genomic estrogen signaling in cardiovascular, oncology, and immunological contexts. It is particularly valuable for distinguishing GPR30-mediated effects from those dependent on classical nuclear estrogen receptors. The compound’s high selectivity enables precise attribution of observed phenotypes to GPR30 activity. In tumor biology, G-1’s nanomolar inhibition of cell migration and proliferation in ER-negative breast cancer lines provides a tool for dissecting hormone-independent signaling pathways (Related internal—this article updates with explicit quantitative migration IC50 data and storage guidance).

Common Pitfalls or Misconceptions

• G-1 does not activate ERα or ERβ at concentrations relevant for GPR30 activation—using G-1 to interrogate nuclear estrogen signaling is inappropriate (Wang et al., 2021).
• Water or ethanol are unsuitable solvents for G-1—solubility is negligible, so DMSO is required for experimental stocks (APExBIO).
• Long-term storage of G-1 solutions at room temperature leads to degradation—solutions should be kept at -20°C and are not recommended for extended storage beyond several weeks (APExBIO).
• G-1 efficacy in vivo is model- and dose-dependent—results in rodents may not generalize directly to human systems without further validation (Related internal—this article clarifies dose-response and translational limits).
• Not all GPR30-expressing cells respond identically—cellular context, receptor density, and downstream effectors modulate response magnitude (Wang et al., 2021).

Workflow Integration & Parameters

G-1 is supplied as a crystalline solid (C₂₁H₁₈BrNO₃, MW 412.28) by APExBIO (product page). For in vitro use, prepare stock solutions at ≥10 mM in DMSO; solubility is ≥41.2 mg/mL. Warming and brief sonication can be used to aid dissolution. Working aliquots should be stored at -20°C, protected from light, and used within several weeks. G-1 is incompatible with aqueous or alcoholic stock solutions. Typical working concentrations in cell assays range from 1 nM to 1 μM, with titration recommended for optimal signal-to-noise. In in vivo studies, dosing regimens must be tailored to species, route, and disease state, with published rodent protocols ranging from 10–50 μg/kg/day intraperitoneally for up to 6 weeks (Wang et al., 2021).

Conclusion & Outlook

G-1 (CAS 881639-98-1) is a benchmark tool for dissecting GPR30-mediated rapid estrogen signaling with unmatched selectivity and efficacy. Its robust performance in cardiovascular, immune, and cancer models—backed by clear mechanistic and operational parameters—supports its continued adoption for foundational and translational research. Ongoing studies are refining its dose-response characteristics and expanding its utility across additional disease models. For further scenario-driven design and protocol troubleshooting, refer to our scenario-driven solutions guide, which this article extends by providing updated quantitative benchmarks and storage recommendations.